



Schweizerische Pädiatrische Onkologie Gruppe
Groupe d'Oncologie Pédiatrique Suisse
Gruppo d'Oncologia Pediatrica Svizzera
Swiss Paediatric Oncology Group

BEACON:

Neuroblastoma is the most common extracranial solid tumour in childhood and the principal cause of death due to cancer in infancy. Although some children and young people with neuroblastoma can be cured with current first line treatment, sometimes, the disease may initially respond to treatment but can soon come back again and need further therapy. Moreover, some neuroblastoma may be particularly resistant to standard treatment.

There is currently no internationally agreed way of treating neuroblastoma that has relapsed or is resistant to current therapies (refractory) and many different treatment combinations are currently used. One common chemotherapy regimen is Temozolomide in combination with Topotecan. There is also a need to try out new treatments in neuroblastoma in the hope of improving cure rates. One new way of treating cancers is to use monoclonal antibodies. They are usually used alongside chemotherapy. In this study we would like to gain further information about the combination of a monoclonal antibody in combination with chemotherapy compared to using chemotherapy on its own.

Contact details for the sponsor representative in Switzerland:

Partner Relations
Centre de coordination du SPOG
Effingerstrasse 33
3008 Berne
Tél.: +41 31 389 91 89